Eur Rev Med Pharmacol Sci 2016; 20 (5): 792-793

Comment on “Peripheral blood used in place of bone marrow aspirate for detection of translocation t(11;14) status during minimal residual disease monitoring is cost-effectiveness”

D. Valente A. Rainone

Cetac Research Center, Caserta (CE), Italy. daniela.valente@aruba.it

Free PDF Download

To cite this article

D. Valente A. Rainone
Comment on “Peripheral blood used in place of bone marrow aspirate for detection of translocation t(11;14) status during minimal residual disease monitoring is cost-effectiveness”

Eur Rev Med Pharmacol Sci
Year: 2016
Vol. 20 - N. 5
Pages: 792-793

Keywords Related articles:

  1. Peripheral blood used in place of bone marrow aspirate for detection of translocation t(11;14) status during minimal residual disease monitoring is cost-effectiveness
  2. Comment on “Tegafur gimeracil oter combined with oxaliplatin for advanced colorectal cancer.” Is it cost effectiveness?
  3. Comparison of minimal residual disease (MRD) monitoring by WT1 quantification between childhood acute myeloid leukemia and acute lymphoblastic leukemia
  4. Quantitative PCR detection of t(11;14) bcl-1/JH in mantle cell lymphoma patients: comparison of peripheral blood and bone marrow aspirate samples
  5. From stem cell to solid organ. Bone marrow, peripheral blood or umbilical cord blood as favorable source?